Investment analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.
Enzo Biochem Stock Performance
Shares of ENZ stock opened at $0.50 on Wednesday. Enzo Biochem has a 12 month low of $0.41 and a 12 month high of $1.40. The company’s fifty day moving average price is $0.68 and its 200-day moving average price is $0.96.
Enzo Biochem (NYSE:ENZ – Get Free Report) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.
Institutional Trading of Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- Stock Market Upgrades: What Are They?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- ESG Stocks, What Investors Should Know
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- How to Buy Cheap Stocks Step by Step
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.